Replies to post #253450 on Biotech Values

[DewDiligence]

CTLT’s acquisition by NVO’s holding company goes through, despite high-profile attempts to block it:

https://www.businesswire.com/news/home/20241213700784/en

This $16.5B deal, whose impetus is increasing NVO’s manufacturing capacity for Wegovy, was announced 10 months ago (#msg-173773953); however, the prominence of the obesity-drug sector generated a lot of opposition (#msg-175290291).